MCL PATIENTS RESPOND TO CDK4/6 INHIBITION

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 04期
关键词：
D O I：
10.1158/2159-8290.CD-RW2012-036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：300 / 300
页数：1
相关论文
共 50 条
  • [21] Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
    Rihani, Ali
    Vandesompele, Jo
    Speleman, Frank
    Van Maerken, Tom
    CANCER CELL INTERNATIONAL, 2015, 15
  • [22] CDK4/6 inhibitors
    不详
    CHEMICAL & ENGINEERING NEWS, 2016, : 30 - 31
  • [23] PHARMACEUTICAL INHIBITION OF CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) IN GLIOBLASTOMA
    Nuga, Oluwademilade
    Meng, Yuling
    Berezovsky, Artem
    Nelson, Kevin
    deCarvalho, Ana
    NEURO-ONCOLOGY, 2020, 22 : 94 - 95
  • [24] Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA.
    Silva, Dilru
    Kinsey, Conan
    McMahon, Martin
    CANCER RESEARCH, 2021, 81 (22) : 22 - 23
  • [25] CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance
    Schaefer, Inga-Marie
    Hemming, Matthew L.
    Lundberg, Meijun Z.
    Serrata, Matthew P.
    Goldaracena, Isabel
    Liu, Ninning
    Yin, Peng
    Paulo, Joao A.
    Gygi, Steven P.
    George, Suzanne
    Morgan, Jeffrey A.
    Bertagnolli, Monica M.
    Sicinska, Ewa T.
    Marino-Enriquez, Adrian
    Hornick, Jason L.
    Raut, Chandrajit P.
    Demetri, George D.
    Ou, Wen-Bin
    Saka, Sinem K.
    Fletcher, Jonathan A.
    CLINICAL CANCER RESEARCH, 2022, 28 (18)
  • [26] MEDULLOBLASTOMAS RESPOND TO CDK4/6 INHIBITION WITH NANOPARTICLE-DELIVERED PALBOCICLIB WITH ALTERED S-PHASE PROGRESSION
    Dismuke, Taylor
    Lim, Chaemin
    Gershon, Timothy
    NEURO-ONCOLOGY, 2019, 21 : 94 - 94
  • [27] CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
    Pita, Jaime M.
    Raspe, Eric
    Coulonval, Katia
    Decaussin-Petrucci, Myriam
    Tarabichi, Maxime
    Dom, Genevieve
    Libert, Frederick
    Craciun, Ligia
    Andry, Guy
    Wicquart, Laurence
    Leteurtre, Emmanuelle
    Tresallet, Christophe
    Marlow, Laura A.
    Copland, John A.
    Durante, Cosimo
    Maenhaut, Carine
    Cavaco, Branca M.
    Dumont, Jacques E.
    Costante, Giuseppe
    Roger, Pierre P.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [28] Molecular dissection of CDK4/CyclinD1 regulation: Prevention of pathway hyperactivation by continuous CDK4/6 inhibition
    Gharbi, S.
    Gutierrez, J.
    Espada, A.
    Gutierrez, S. M.
    Torres-Guzman, R.
    Debets, M. F.
    Prieto, L.
    Du, J.
    De Dios, A.
    Lallena, M. J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E45 - E45
  • [29] Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
    Maurer, Barbara
    Brandstoetter, Tania
    Kollmann, Sebastian
    Sexl, Veronika
    Prchal-Murphy, Michaela
    HAEMATOLOGICA, 2021, 106 (10) : 2624 - 2632
  • [30] CDK4/6 INHIBITION FOR THE TREATMENT OF ATYPICAL TERATOID/RHABDOID TUMORS
    Hashizume, Rintaro
    Gragg, Ashley
    Muller, Sabine
    Banerjee, Anuradha
    Phillips, Joanna
    Prados, Michael
    Haas-Kogan, Daphne
    Gupta, Nalin
    James, David
    NEURO-ONCOLOGY, 2011, 13 : 113 - 113
12345